This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Subscribe To Our Newsletter & Stay Updated
